Skip to main content
Midas Edge

Tarsus Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

TARS$73.83+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consol idated Statements of Stockholders’ Equity

(In thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202542,553,931$6$769,667$381$(426,628)$343,426
Net loss————(6,967)(6,967)
Recognition of stock-based compensation expense——11,967——11,967
Exercise of vested stock options45,394—1,204——1,204
Issuance of common stock upon the vesting of restricted stock units421,987—————
Other comprehensive income (loss)———(679)—(679)
Balance as of March 31, 202643,021,312$6$782,838$(298)$(433,595)$348,951
Net loss————(18,551)(18,551)
Recognition of stock-based compensation expense——13,289——13,289
Exercise of vested stock options91,548—1,864——1,864
Issuance of common stock upon the vesting of restricted stock units131,601—————
Shares issued in connection with the employee stock purchase plan26,886—1,438——1,438
Other comprehensive income (loss)———(259)—(259)
Balance as of June 30, 202643,271,347$6$799,429$(557)$(452,146)$346,732
Net loss————(668,334)(668,334)
Recognition of stock-based compensation expense——27,218——27,218
Issuance of common stock in private placement, net of issuance costs of $4.6 million2,098,519—112,923——112,923
Issuance of pre-funded warrants in private placement, net of issuance costs of $0.3 million——7,190——7,190
Common stock issued for acquisition of Alkeus2,908,6921230,466——230,467
Common stock issued to securityholders of iRenix607,093—40,706——40,706
Exercise of vested stock options309,746—7,484——7,484
Issuance of common stock upon the vesting of restricted stock units108,016—————
Other comprehensive income (loss)———(357)—(357)
Balance as of September 30, 202649,303,413$7$1,225,416$(914)$(1,120,480)$104,029
Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202438,349,826$6$584,559$179$(360,210)$224,534
Net loss————(25,120)(25,120)
Recognition of stock-based compensation expense——6,930——6,930
Issuance of common stock, net of issuance costs of $9.0 million3,230,336—134,771——134,771
Exercise of vested stock options78,436—1,437——1,437
Issuance of common stock upon the vesting of restricted stock units336,939—————
Other comprehensive income (loss)———(94)—(94)
Balance as of March 31, 202541,995,537$6$727,697$85$(385,330)$342,458
Net loss————(20,340)(20,340)
Recognition of stock-based compensation expense——8,234——8,234
Exercise of vested stock options56,795—1,205——1,205
Issuance of common stock upon the vesting of restricted stock units126,639—————
Shares issued in connection with the employee stock purchase plan32,001—1,101——1,101
Other comprehensive income (loss)———(46)—(46)
Balance as of June 30, 202542,210,972$6$738,237$39$(405,670)$332,612
Net loss————(12,585)(12,585)
Recognition of stock-based compensation expense——12,243——12,243
Exercise of vested stock options127,085—2,562——2,562
Issuance of common stock upon the vesting of restricted stock units109,825—————
Other comprehensive income (loss)———250—250
Balance as of September 30, 202542,447,882$6$753,042$289$(418,255)$335,082
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.